Stocktoria
Fulcrum Therapeutics, Inc. FULC
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2019-07-18
Fulcrum Therapeutics, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $80.0M | $2.8M | $6.3M | $19.2M |
| R&D expense | $56.1M | $63.4M | $71.8M | $76.8M | $69.7M |
| Operating income | -$84.8M | -$21.9M | -$110.7M | -$112.6M | -$81.1M |
| Income tax | $0 | $0 | — | — | — |
| Net income | -$74.9M | -$9.7M | -$97.3M | -$109.9M | -$80.8M |
| EPS (diluted) | $-1.18 | $-0.16 | $-1.59 | $-2.44 | $-2.29 |
| Operating cash flow | -$60.1M | -$2.2M | -$91.0M | -$97.0M | -$78.5M |
| Free cash flow | -$60.4M | -$2.5M | -$91.5M | -$99.0M | -$80.2M |
| Cash & equivalents | $197.5M | $58.2M | $25.6M | $35.1M | $35.4M |
| Total assets | $366.3M | $260.7M | $257.7M | $226.7M | $235.0M |
| Total liabilities | $17.3M | $17.7M | $22.5M | $27.7M | $23.5M |
| Shareholders' equity | $349.0M | $243.0M | $235.2M | $198.9M | $211.5M |
Source: SEC EDGAR filings · CIK 0001680581 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.